We therefore restricted our analysis to LUAD patients with tissue-enriched CD4+, CD8+, and NK T cells, and found those with higher IL-17RC levels had a trend of being associated with a poorer prognosis (p = 0.056) (Figure 3B), and this correlation was more striking in the population with a high tumor mutation burden (p = 0.0041) (Figure 3C). The gene discussed is IL17RC; the disease is neoplasm.